|
Market Closed -
04:00:02 2026-08-20 pm EDT
|
5-day change
|
1st Jan Change
|
|
291.45 USD
|
+0.50%
|
 |
+3.62%
|
+46.10%
|
|
Aug. 20 |
Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing
|
MT
| |
Aug. 20 |
Charles River, Medigen Partner on Multivalent Enterovirus Vaccine
|
MT
| |
Aug. 20 |
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
|
BU
| |
Aug. 13 |
Charles River Laboratories International Insider Sold Shares Worth $1,038,657, According to a Recent SEC Filing
|
MT
| |
Aug. 10 |
TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating
|
MT
| |
Aug. 10 |
Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating
|
MT
| |
Aug. 06 |
Charles River Laboratories International Insider Sold Shares Worth $1,327,098, According to a Recent SEC Filing
|
MT
| |
Aug. 06 |
Barclays Adjusts Price Target on Charles River Laboratories International to $300 From $220
|
MT
| |
Aug. 06 |
RBC Adjusts PT on Charles River Laboratories International to $282 From $215, Keeps Outperform Rating
|
MT
| |
Aug. 06 |
Deutsche Bank Adjusts Charles River Laboratories International PT to $300 From $260, Maintains Buy Rating
|
MT
| |
Aug. 06 |
JPMorgan Upgrades Charles River Laboratories International to Overweight From Neutral, Adjusts PT to $310 From $180
|
MT
| |
Aug. 05 |
Top Midday Gainers
|
MT
| |
Aug. 05 |
Charles River Laboratories International, Inc., Q2 2026 Earnings Call, Aug 05, 2026
| | |
Aug. 05 |
Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.
|
CI
| |
Aug. 05 |
Charles River Laboratories International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 27, 2026
|
CI
| |
Aug. 05 |
Charles River Laboratories Fiscal Q2 Non-GAAP Earnings, Revenue Fall; Lifts 2026 Guidance
|
MT
| |
Aug. 05 |
Charles River Laboratories International, Inc. Updates Earnings Guidance for 2026
|
CI
| |
Aug. 05 |
(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $11.15 - $11.45, vs. FactSet Est of $11.11
|
MT
| |
Aug. 05 |
Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Revenue $1.00B, vs. FactSet Est of $977.2M
|
MT
| |
Aug. 05 |
Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Adjusted EPS $3.02, vs. FactSet Est of $2.74
|
MT
| |
Aug. 05 |
Charles River lifts profit forecast on improving biotech demand
|
RE
| |
Aug. 05 |
Charles River: Q2 Earnings Snapshot
|
AQ
| |
Aug. 05 |
Charles River Laboratories Announces Second-Quarter 2026 Results
|
BU
| |
Jul. 15 |
Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call
|
BU
| |
Jul. 13 |
BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220
|
MT
|
No results match your criteria Select your edition All financial news and data tailored to specific country editions | 
